HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,712 | +10.3% | 44,820 | +4.2% | 0.01% | 0.0% |
| Q2 2023 | $1,552 | +38.3% | 43,030 | +46.5% | 0.01% | +25.0% |
| Q1 2023 | $1,122 | -61.2% | 29,375 | -42.2% | 0.00% | -63.6% |
| Q4 2022 | $2,890 | -99.8% | 50,789 | +19.1% | 0.01% | +57.1% |
| Q3 2022 | $1,687,000 | +1.3% | 42,658 | +12.7% | 0.01% | 0.0% |
| Q2 2022 | $1,665,000 | +38.2% | 37,840 | +25.2% | 0.01% | +40.0% |
| Q1 2022 | $1,205,000 | +14.0% | 30,219 | +14.9% | 0.01% | +25.0% |
| Q4 2021 | $1,057,000 | -13.1% | 26,291 | -12.1% | 0.00% | -20.0% |
| Q3 2021 | $1,217,000 | -20.5% | 29,920 | -11.2% | 0.01% | -28.6% |
| Q2 2021 | $1,530,000 | +15.8% | 33,693 | +6.3% | 0.01% | 0.0% |
| Q1 2021 | $1,321,000 | +32.2% | 31,704 | +35.5% | 0.01% | +16.7% |
| Q4 2020 | $999,000 | -27.3% | 23,392 | -55.3% | 0.01% | -33.3% |
| Q3 2020 | $1,375,000 | -1.7% | 52,317 | +0.2% | 0.01% | 0.0% |
| Q2 2020 | $1,399,000 | – | 52,187 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |